- Companies like INmune Bio are advancing the development of innovative treatment methods
- INmune’s lead drug candidate, XPro1595, works by targeting neuroinflammation, one of the causes of Alzheimer’s
- XPro1595 is set to undergo a phase I clinical trial in the summer of 2019 with a goal of measuring traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer’s
The global market for Alzheimer’s disease (AD) treatments is forecast to double in value by 2023, reaching $4.9 billion, according to GlobalData research (http://nnw.fm/e2TV5). The growth rate has been estimated at 10.5 percent for the forecast period.
The increasing prevalence of Alzheimer’s disease, advanced diagnostic capabilities and technological advances are all expected to contribute to the future growth. Companies like INmune Bio Inc. (NASDAQ: INMB) are working hard on such technological and pharmaceutical advances. The clinical-stage immunology company is developing novel therapies that affect a specific part of the patient’s immune system to produce a disease-fighting response.
The company’s drug candidate, XPro1595, targets neuroinflammation – one of the causes of AD.
In June 2019, Pfizer researchers announced an important discovery highlighting the connection between neuroinflammation and AD. Medications that work in a manner similar to XPro1595 reduce the risk of AD development by as much as 64 percent. The Pfizer research confirms previous studies on the topic. A 2016 analysis of 8.5 million individuals showed that patients given medications suppressing neuroinflammation were less likely to develop AD than controls (http://nnw.fm/T5cMq).
An association between inflammation and Alzheimer’s disease has long been established. Until present, however, this link and the way in which it could be used to offer reliable AD treatments have both been overlooked. Numerous inflammatory markers are found in AD patients and several studies establish a link between chronic inflammation and the development of AD.
XPro1595 works by targeting the microglial immune cells of the brain. These cells are activated in many AD patients. They cause neuroinflammation that kills nerve cells and promotes synaptic dysfunction. Combined, these two effects lead to dementia in people with AD.
XPro1595 is currently undergoing strenuous testing. A three-month, phase I trial will involve 18 patients and will be carried out in the summer of 2019. Through the trial, INmune Bio will measure traditional and novel biomarkers of inflammation in people with mild to moderate AD. The Alzheimer’s Association is supporting the trial financially through the provision of a $1 million grant.
Such clinical work is of especially high importance due to AD developments over the past few years. The prevalence of AD doubles every five years, a report titled ‘Alzheimer’s Disease – Competitive Landscape and Market’ suggests (http://nnw.fm/GK1Zt). The prevalence of the condition has reached 40 percent of the 90-94 age group. The World Health Organization (WHO) reports that AD prevalence is also set to increase by in those aged 65 or older, from 6.8 percent in 2000 to 16.2 percent by 2050. The prevalence of dementia as a consequence is anticipated to increase from 24 million cases in 2005 to 81 million cases in 2040.
Based in La Jolla, California, INmune Bio is a diversified clinical-stage biotechnology company working to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. With its programs in oncology and neurodegenerative disease, the company offers intriguing investment opportunities.
For more information, visit the company’s website at www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
